CAR‑T cell therapy : A breakthrough in traditional cancer treatment strategies (Review)
Chimeric antigen receptor (CAR)‑T cell therapy is an innovative approach to immune cell therapy that works by modifying the T cells of a patient to express the CAR protein on their surface, and thus induce their recognition and destruction of cancer cells. CAR‑T cell therapy has shown some success in treating hematological tumors, but it still faces a number of challenges in the treatment of solid tumors, such as antigen selection, tolerability and safety. In response to these issues, studies continue to improve the design of CAR‑T cells in pursuit of improved therapeutic efficacy and safety. In the future, CAR‑T cell therapy is expected to become an important cancer treatment, and may provide new ideas and strategies for individualized immunotherapy. The present review provides a comprehensive overview of the principles, clinical applications, therapeutic efficacy and challenges of CAR‑T cell therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Molecular medicine reports - 29(2024), 3 vom: 24. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Dahua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse effects |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 04.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3892/mmr.2024.13171 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367655381 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367655381 | ||
| 003 | DE-627 | ||
| 005 | 20240204232008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/mmr.2024.13171 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1280.xml |
| 035 | |a (DE-627)NLM367655381 | ||
| 035 | |a (NLM)38275119 | ||
| 035 | |a (PII)47 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Dahua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CAR‑T cell therapy |b A breakthrough in traditional cancer treatment strategies (Review) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 04.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Chimeric antigen receptor (CAR)‑T cell therapy is an innovative approach to immune cell therapy that works by modifying the T cells of a patient to express the CAR protein on their surface, and thus induce their recognition and destruction of cancer cells. CAR‑T cell therapy has shown some success in treating hematological tumors, but it still faces a number of challenges in the treatment of solid tumors, such as antigen selection, tolerability and safety. In response to these issues, studies continue to improve the design of CAR‑T cells in pursuit of improved therapeutic efficacy and safety. In the future, CAR‑T cell therapy is expected to become an important cancer treatment, and may provide new ideas and strategies for individualized immunotherapy. The present review provides a comprehensive overview of the principles, clinical applications, therapeutic efficacy and challenges of CAR‑T cell therapy | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adverse effects | |
| 650 | 4 | |a chimeric antigen receptor T cell therapy | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a malignant tumors | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 700 | 1 | |a Shi, Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Sanyan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaohua |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Meiping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular medicine reports |d 2008 |g 29(2024), 3 vom: 24. Feb. |w (DE-627)NLM192195727 |x 1791-3004 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2024 |g number:3 |g day:24 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/mmr.2024.13171 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2024 |e 3 |b 24 |c 02 | ||